Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist PegvisomantPeter Trainer, John A. Scarlett, William M Drake et al.|New England Journal of Medicine|2000Cited by 874
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonistAart Jan van der Lely, Michael O. Thorner, R. Kent Hutson et al.|The Lancet|2001Cited by 643
Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure<sup>1</sup>Gudmundur Johannsson, Bengt‐Åke Bengtsson, Per Mårin et al.|The Journal of Clinical Endocrinology & Metabolism|1997Cited by 335
Growth Hormone Research Society perspective on the development of long-acting growth hormone preparationsJens Sandahl Christiansen, Kevin C.J. Yuen, Margaret Cristina da Silva Boguszewski et al.|European Journal of Endocrinology|2016Cited by 144
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statementMargaret Cristina da Silva Boguszewski, Gudmundur Johannsson, César Luiz Boguszewski et al.|European Journal of Endocrinology|2022Cited by 111